Novo Nordisk's (NOVOB DC) CFO says there is still very low penetration in the Chinese obesity drug market as competition has been intense
Importance
Level 1
- They are expecting a percentage decline in 2026 US sales in the teens.
#CHINA#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#EUROPEAN EQUITIES